Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
EONTEC'S LIQUIDMETAL IS SELECTED AS NATIONAL INDIVIDUAL MANUFACTURING PRODUCT CHAMPION 20
/R/LQMT, 2022-11-01, 03:25:52
https://ex-chinadaily-com-cn.translate.goog/exchange/partners/82/rss/channel/cn/columns/snl9a7/stories/WS635f5cf7a310817f312f3bde.html?_x_tr_sch=http&_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en
On October 24, the Guangdong Provincial Department of Industry and Information Technology announced the "Review of the Seventh Batch of National Manufacturing Individual Champion Enterprises (Products) in Guangdong Province and the First and Fourth Batch of National Manufacturing Individual Champion Enterprises (Products)" Through the List", the LiquidMetal of the A-share listed company Eontec was selected by the Ministry of Industry and Information Technology and the China Federation of Industry to select the seventh batch of national-level manufacturing individual champion enterprises (products) list, Eontec was shortlisted. It means that Eontec and LiquidMetal have been highly recognized by relevant departments.
The list of the seventh batch of national-level manufacturing individual champion enterprises (products) includes 9 individual champion demonstration enterprises and 18 individual champion products. A number of high-tech listed companies in Guangdong Province, including Micro and Wanhe Electric, are on the list.
It is understood that the selection of national-level manufacturing single champion enterprises (products) is carried out by the Ministry of Industry and Information Technology in conjunction with the China Federation of Industry Provide guidance, carry out storage and cultivation of potential enterprises, and strengthen precise services for outstanding problems faced by individual champion enterprises.
The Ministry of Industry and Information Technology and the China Federation of Industry and Commerce have set very high selection conditions for the champion applicant companies or declared products, and have put forward clear and detailed requirements in terms of product research and development, market share and growth. Champion enterprises require long-term focus and deep cultivation in a certain link of the industrial chain or a certain product field, attach importance to R&D investment and have independent core intellectual property rights, and lead or participate in the formulation of technical standards in related fields; for champion products, in addition to the above conditions, the company also requires The product market share ranks among the top three in the world.
In addition to the excellent material properties of the LiquidMetal products it produces, the LiquidMetal of Eontec can be selected as the national single champion product in the manufacturing industry, and its flexural strength, tensile strength, elastic deformation, etc. are significantly better than commonly used metals. In addition to material products, Eontec has the world's largest LiquidMetal industrialization base and independent core technology, forming a complete industrial chain of "material-equipment-process", and its product market share is far ahead of other companies.
As early as more than ten years ago, the industrial application of LiquidMetal was only in the theoretical stage, Professor Lugee Li, the leader of Eontec, had insight into the huge industrial application prospects and value of LiquidMetal, and listed LiquidMetal as the strategic development direction of Eontec; Years of hard work have successfully broken through the bottleneck of LiquidMetal industrialization. At present, Eontec's LiquidMetal products are currently widely used in folding screen mobile phone hinges, automotive structural parts, high-end headphones, medical equipment and other fields. In particular, the rise of the folding screen mobile phone market in the past two years has opened up a huge market space for the company's LiquidMetal products; it has also established Eontec's industry leadership in LiquidMetal.
For more than ten years, Eontec, with its precise strategic vision and strong strategic determination, has overcome the difficulties that must be encountered in the research and development of new material applications. The development of the industry has drawn a clear development prospect.
Benefiting from the continuous support of national policies and the deepening understanding of LiquidMetal in related industries, more and more companies have used LiquidMetal materials to design and manufacture complex structural parts with high performance and high precision. continue to expand. In the future, Eontec will continue to use its own advantages to strengthen industry exchanges and cooperation, and jointly promote the application and development of the LiquidMetal industry with relevant parties.
Fatigue Pipeline Therapeutics H2 Assessment of Drug Target, MoA and Molecule Type in 2017 New Research Report at RnRMarketResearch.com
Posted: Jul 13, 2017 9:20AM CDT
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com
SOURCE RnRMarketResearch
PUNE, India, July 13, 2017 /PRNewswire/ --
Fatigue Pipeline Review, H2 2017 is new Central Nervous System report analysis includes 34 pages with covers pipeline products based on several stages of development key companies, drugs profile ranging from pre-registration till discovery and undisclosed stages.
Fatigue also referred to as tiredness, exhaustion, lethargy, listlessness, and describes a physical and/or mental state of being tired and weak. Signs and symptoms include aching or sore muscles, painful lymph nodes, chronic (long-term) tiredness, dizziness, headache, irritability and loss of appetite.
Complete report on Fatigue Pipeline Review, H2 2017 spread across 34 pages is available at http://www.rnrmarketresearch.com/fatigue-pipeline-review-h2-2017-market-report.html .
Fatigue - Companies Involved in Therapeutics Development : Aoxing Pharmaceutical Company Inc, BioLite Inc, Chronos Therapeutics Ltd, Merz Pharma GmbH & Co KgaA, MultiCell Technologies Inc
Fatigue - Drug Profiles: anamorelin hydrochloride, BLI-1402, caffeine, CTDP-001, MRZ-9547, phenylbutyrate
Pharmaceutical and Healthcare latest pipeline guide Fatigue - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Fatigue (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Order a copy of this research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=1134735 .
The Fatigue (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Fatigue and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Unknown stages are 2, 1, 3 and 1 respectively.
Fatigue (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Related reports on Central Nervous System category
Sedation - Pipeline Review, H2 2017
The Sedation (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Sedation and features dormant and discontinued projects. Key players are Drawbridge Pharmaceuticals Pty Ltd, Jiangsu Hengrui Medicine Co Ltd, Jiangsu Nhwa Pharmaceutical Corp Ltd, Paion AG, Primex Pharmaceuticals Oy, The Medicines Company, Therakind Ltd.
Explore more reports of Therapeutics Market Research at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics
About Us:
RnRMarketResearch.com is your one stop market research and industry analysis reports' library providing business data and intelligence information on thousands of micro markets with global as well as regional coverage. Category focused research, country reports, company profiles, regional and global industry profiles and guides to premium reports offering extensive coverage of other 20+ industries are all available in our library of syndicated market research reports.
Contact:
Ritesh Tiwari
2nd Floor, Metropole,
Bund Garden Road,
Pune - 411001,
India.
Tel: +1-888-391-5441
E-mail: sales@rnrmarketresearch.com
©2017 PR Newswire. All Rights Reserved.
KEPCO AND KBRIDGE LINK- $2 billion nuclear reactor deal with Saudi Arabia
OLD NEWS PUTTING KEPCO AND KBRIDGE TOGETHER.
EX-99 2 exhibit991.htm EXHIBIT 99.1
FOR IMMEDIATE RELEASE
KBRIDGE ENERGY CORP.
5836 S. Pecos Road, Suite 104
Las Vegas, Nevada 89120
N E W S R E L E A S E
Las Vegas, NV –KBridge Energy Corp. announces that, concurrent with its name change from Blue Marble Media Corp. to KBridge Energy Corp. which took place in December 2011, management has elected to change its business sector to natural resource development and related projects. Management believes that acting in a consultancy capacity in this industry has tremendous potential for the company.
KBridge intends to facilitate global resource developers with investments from Korean companies in the energy/resource sector. KBridge will provide resource developers with long-term funding options for successful projects, together with ongoing growth opportunities, while assisting Korean companies in securing resource supplies and advancing into the global resource industry.
With its extensive experience in the natural resource sector and existing connections in Korea and North America, KBridge introduced Korean Electric Power Corporation (“KEPCO”), to Strathmore Minerals Corp. (“STM”), and assisted the companies to enter into a definitive agreement on February 1, 2012 in respect of a phased joint venture development of STM’s Gas Hills, Wyoming uranium properties (the “Properties”). KBridge has agreed to provide advisory consulting services to Strathmore in connection with STM’s negotiations with KEPCO for an equity private placement in STM and for project financing in connection with the exploration and development of STM’s properties and signed consultant's fee agreement with STM dated February 17, 2012,
Strathmore Minerals Corp. is a Canadian based resource company specializing in the strategic acquisition, exploration and development of uranium properties in the United States. Headquartered in Vancouver, British Columbia with a branch administrative office in Kelowna, the Company also has U.S. based Development Offices in Riverton, Wyoming and Santa Fe, New Mexico. Strathmore Minerals Corp. Common Shares are listed on the TSX under the symbol "STM" and trade on the OTCQX International electronic trading system in the United States under the symbol "STHJF".
Korea Electric Power Corporation is a Korean government-invested diversified energy company with over US$120 billion in assets. KEPCO is involved in the generation, transmission and distribution of electrical power from nuclear, hydro, coal, oil and LNG sources worldwide. KEPCO provides electricity to almost all households in Korea and operates 21 nuclear power plants in the country with seven more under development. KEPCO has over 46,000 employees and is listed on the Korean Stock Exchange and the New York Stock Exchange. (www.kepco.co.kr).
Dated at Las Vegas, Nevada, this 24th day of February, 2012.
ON BEHALF OF THE BOARD OF
KBRIDGE ENERGY CORP.
For more information contact Lindsey Shin at (250) 979-6360.
-----------------------------------------------------------------------------------
South Korea to build nuclear reactors for Saudi Arabia
By Reuters
Wednesday, 4 March 2015 1:42 PM
(Image for illustrative purposes only)
Saudi Arabia and South Korea have signed a memorandum of understanding (MOU) to cooperate on the development of nuclear energy, Saudi state news agency SPA said, building on a deal signed in 2011.
South Korean President Park Geun-hye met with Saudi Arabia's King Salman on Tuesday in Riyadh during an official visit, SPA said.
The MOU calls for South Korean firms to help build at least two small-to-medium sized nuclear reactors in Saudi Arabia, the South Korean presidential office said in a statement.
"If the two units go ahead, the cost of the contract will be (near) $2 billion," the statement said.
Saudi Arabia aims to build 17 gigawatts (GW) of nuclear power by 2032 as well as around 41 GW of solar capacity. The oil exporter currently has no nuclear power.
Those plans are likely to take until 2040, the head of the King Abdullah City for Atomic and Renewable Energy (K.A.CARE), in charge of overseeing such projects, said in January.
On Tuesday, K.A.Care said in a statement: "The two sides will discuss the current mutual activities and ways and means of future collaboration, building on the bilateral agreement already signed between the kingdom of Saudi Arabia and the Republic of South Korea in 2011 with a view to develop and apply nuclear energy for peaceful uses."
That agreement called for cooperation in research and development, as well as in construction and training.
Separately, Saudi Electricity signed four energy-related agreements on Tuesday with US company General Electric as well as South Korea's Korea Electric Power Corp (KEPCO), Doosan Heavy Industries and Construction and Eximbank.
The KEPCO agreement calls for cooperation in development of nuclear and renewable energy.
Al Hassan Ghazi Ibrahim Shaker Co. also signed a non-binding MOU with South Korea's LG Electronics on cooperation in cooling systems for nuclear reactors.
The United Arab Emirates was the first Gulf Arab state to start building a nuclear power plant. In December 2009, the UAE awarded a group led by KEPCO a contract to build four 1,400 MW nuclear reactors to meet surging demand for electricity.
CHECK THIS OUT. DM's moving on already. CEO and President of Shades Holdings, Inc.
http://ih.advfn.com/p.php?pid=nmona&article=64923134
BUYER BEWARE!!!!
Iggy Azalea Joins 'Fast & Furious 7'
http://m.etonline.com/movies/149057_iggy_azalea_fast_and_furious_7_vin_diesel/
Iggy Azalea Joins 'Fast & Furious 7'
JULY 30, 2014 | 5:22AM EDT
FULL SIZE IMAGE
Fast & Furious 7 just got a little fancier.
Vin Diesel broke the news that Australian rapper Iggy Azalea stars in the action sequel. "Iggy Azalea and I just worked together two weeks ago," the 47-year-old actor leaked while chatting on SkyrockFM about his new movie Guardians of the Galaxy.
Iggy is going to be the next big thing.
NEWs: NTEK + HHSE partnership = $$$$$$$$
Hannover House VODWIZ Venture Reaches 10-Partner Studios and 2,500+ Titles
Jul 18, 2014
OTC Disclosure & News Service
Los Angeles, CA -
The indie-studio streaming site, VODwiz, will launch with a minimum of ten supplier studio partners and 2,500 titles next month, reports Hannover House, Inc. (OTC: HHSE).
Consumers will have the ability to stream independent films as well as selected major studio fare, with a pay-per-transaction model and prices starting at $.99 per movie. The goal of VODwiz is to become a primary destination for movie consumers looking for more than just "the handful of major hits" that tend to dominate the existing portals for video-on-demand programming and subscription viewing services. VODwiz will operate as both a website streaming service, as well as an Internet Protocol TV service (IPTV) with Roku-enabled operations. Studio-supplier partners and key title selections will be individually announced, beginning next week.
Operations for VODwiz are being handled through a servicing agreement with Nanotech Entertainment, Inc., including the technical steps involved in streaming the films to consumers.
Hannover House and VODwiz will support the launch of the VODwiz site and IPTV venture with a high-visibility campaign, including national consumer advertising, publicity and social media outreach.
This might be why Clark is in NYC.
Trade Shows
By IndustryBy CountryBy DateGadgets
Conferences
All Conferences By IndustryBy CountryBy Date
Organizers
All OrganizersBy IndustryBy Country
Venues
English Online Visitor Pass Book a Stall (Offers) Best Hotel Deals BTS Top 100 Advertise Add New Event
Trade ShowsGifts & HandicraftsUnited States Of AmericaNew York
The Pier Antiques Show
Visitor Registration
OPEN 23 - 24 November 2013 Set Reminder
Pier 94
New York, United States Of America AboutVisitor RegistrationBook a StallBook a Hotel
The Pier Antiques Show is a largest & Most Comprehensive Art & Antiques Event of the New York and related to Ceramics & Porcelains, Rugs, All Eras and All Vintage products, the event will attract many visitors and more than 500 dealers/exhibits with 3000 booth.
IDEAL BIOSTENT???
Dissolvable stents to be sold in India
Malathy Iyer, TNN Dec 15, 2012, 04.01AM IST
Senior cardiologist|Jaslok Hospital|Drug Controller General|Ashok Seth|Abbott Vascular|Abbott
MUMBAI: Cardiac patients across India will soon have a new option while seeking treatment for their hearts. Within the next 10 days, they can ask for a bio-absorbable stent, which will completely disappear some 18-odd months after it's fixed in their blocked blood vessel. At present, metallic stents that permanently stay in the blood vessel are the most-sought-after treatment for cardiac diseases.
The bio-absorbable stent's upcoming commercial launch follows an approval given by the Drug Controller General of India to multinational firm Abbott Vascular after a review of the results of a trial, involving 100 patients. "The patients were doing well during a six-month follow-up. The results are as good as metallic stents," said the trial's Delhi-based principal investigator Dr Ashok Seth.
Each of these stents will cost around Rs 3 lakh
However, the drug-coated absorbable stent comes with a premium price tag. "It will cost Rs 2.85 to 3 lakh each, and the entire hospitalization may cost a patient over Rs 4 lakh for a single stent," said a hospital administrator. In contrast, imported drug-coated permanent metallic stents cost Rs 1.3 lakh each. Senior cardiologist Dr A B Mehta, of Jaslok Hospital, said, "The absorbable stent may only be used for a few wealthy people in the city." However, Seth said, "We are still negotiating the cost with the company as the absorbable stent will be beyond the reach of the common man in India."
But experts said there is no denying that the absorbable stent is an evolution. "It's the dawning of a new era. From using balloons in the 1970s, we have now evolved to absorbable stents," said Dr Ganesh Kumar, of Hiranandani Hospital, Powai. He said the bio-absorbable device, in fact, should be called a scaffolding and not a stent. "A stent is a permanent metallic device, while this one will dissolve completely within two years," he added.
Experts list three major advantages of the absorbable scaffolding. "There is no question of stent thrombosis (clotting) because the scaffolding dissolves," said Mehta. Seth said the biggest advantage is that patients will not need to take two anti-platelet (blood-thinning) medicines for years on end. City-based cardiologist V T Shah said patients will need to take two blood-thinners till the scaffolding dissolves. "Thereafter, they will need to take only one for up to two years," he added. Long-term studies will show whether blood thinners need to be taken at all in the long run.
At present, patients with stents can never be asked to stop taking their blood thinners for fear of some clotting occurring in the stent. "So patients with stents who need to undergo another operation, such as knee replacement or dental implants, are at risk of excessive bleeding. They cannot risk stopping the blood thinners," said Shah.
The scaffolding may be the best invention for cardiac patients who require treatment in their 30s or 40s. "The scaffolding will dissolve and doctors can use any mode of treatment in the future, even a cardiac bypass surgery," said Seth.
I agree with you, though did you read the last paragraph when they talk about apple!
Good morning, I've been following this board since April 2012. Found an interesting article that I'd like to share, wasn't able to find a date but the last paragraph says a lot.
http://www.virtualacquisitionshowcase.com/document/1472/briefing